Feb 15, 2017 04:11 PM IST | Source:

Buy Aurobindo Pharma; target of Rs 917: Khambatta Securities

Khambatta Securities is bullish on Aurobindo Pharma has recommended buy rating on the stock with a target price of Rs 917 in its research report dated February 13, 2017.

  • bselive
  • nselive
Todays L/H

Khambatta Securities' research report on Aurobindo Pharma

Aurobindo’s revenues grew 12.6% y-o-y and 3.4% q-o-q to Rs 39,141 mn in 3Q FY17 marginally above our expectations. Revenue was driven by 12.0% y-o-y growth in US formulations and 10.3% growth in Europe formulations business while ARVs grew 12.0% y-o-y during the quarter. API sales grew 11.6% y-o-y during the quarter.


We assume a target EV/EBITDA multiple of 13x for FY 2018 EBITDA, to arrive at a target price of Rs 919 per share. Aurobindo’s DCF valuation is Rs 914 per share. Consequently, using a weighted average methodology we arrive at a share price of Rs 917, generating a 38.8% upside potential in the medium term.

For all recommendations, click here

The views and investment tips expressed by investment experts/broking houses/rating agencies on are their own, and not that of the website or its management. advises users to check with certified experts before taking any investment decisions.
Follow us on
Available On